University of Nebraska
The purpose of this randomized phase II trial is to compare dose escalation of the prostate versus the dominant intra-prostatic lesion in a reduced fraction radiation therapy regimen.
This is a phase 2 randomized clinical trial evaluating two dose escalation strategies during prostate stereotactic body radiotherapy (SBRT). A total of 160 patients with prostate adenocarcinoma will be enrolled and randomized in a 1:1 ratio to one of two treatment arms. 160 patients will be enrolled in this study over 3.2 years. Eligible participants will be stratified by risk group and tamsulosin use and randomized to one of two treatment arms. Both arms will receive 3625 cGy to the prostate plus planning margin delivered over 5 fractions. Arm A will receive an additional boost of 4000 cGy t…
Inclusion Criteria: 1. Adults ≥19 years of age 2. Patients with a diagnosis of prostate adenocarcinoma for whom SBRT to the prostate +/- proximal seminal vesicles is being offered 3. Prostate gland volume less than 100 cc prior to initiation of ADT as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities, including MRI or CT scan 4. PI-RADS 4 or 5 lesion seen on pretreatment MRI 5. IPSS/AUA (Appendix D, E) symptom score less than 16 Exclusion Criteria: 1. Prior treatment for prostate cancer 2. Prior solid cancer diagnosis in the last 5 years 3. Any hi…
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost to the dominant intra-prostatic lesion.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.